It all points to 12 mths dedicated to maximising bed coverage by trading off short term margin (per bed cost). I assume the strategy here will be that broader coverage means more data and more opportunity to prove the efficacy and benefits of painchek.
With a fact base confirming it works, saves time, creates better outcomes for patients etc then RACs will be happy to pay the usual per bed rate to keep painchek. No churn rate so far remember. Not to mention an easy box for the government to tick by simply continuing ongoing funding.
As you've outlined, it does suggest we may not see exponential revenue growth as much as we may have wanted, just exponential growth in active beds over the year.
In 12mths time would you rather have 100,000 beds at $5 per bed per month, or 250,000 at $2 per month for the first 12mths, which will then increase to a still discounted $4 per bed per month (for example) without any additional efforts by the company other than a contract renewal. It's this year 2 and 3 per bed price uplift that is very important imo.
There's other software out there that have to be given away for free trials. Our customers are paying for this already and the government is paying new customers to jump on board.
PCK Price at posting:
22.5¢ Sentiment: Buy Disclosure: Held
